JP2011088897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011088897A5
JP2011088897A5 JP2010253233A JP2010253233A JP2011088897A5 JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5 JP 2010253233 A JP2010253233 A JP 2010253233A JP 2010253233 A JP2010253233 A JP 2010253233A JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5
Authority
JP
Japan
Prior art keywords
apo
ligand
formulation
metal ions
divalent metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010253233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011088897A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011088897A publication Critical patent/JP2011088897A/ja
Publication of JP2011088897A5 publication Critical patent/JP2011088897A5/ja
Pending legal-status Critical Current

Links

JP2010253233A 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 Pending JP2011088897A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001506824A Division JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Publications (2)

Publication Number Publication Date
JP2011088897A JP2011088897A (ja) 2011-05-06
JP2011088897A5 true JP2011088897A5 (enExample) 2012-02-02

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法

Country Status (12)

Country Link
US (3) US7855066B1 (enExample)
EP (3) EP1194555B1 (enExample)
JP (2) JP5118796B2 (enExample)
KR (1) KR100674528B1 (enExample)
CN (2) CN100526463C (enExample)
AU (3) AU6338200A (enExample)
CA (1) CA2377585A1 (enExample)
ES (1) ES2392392T3 (enExample)
IL (2) IL147029A0 (enExample)
MX (1) MXPA01013236A (enExample)
NZ (2) NZ515990A (enExample)
WO (1) WO2001000832A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
US20060141561A1 (en) * 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
CA2946323A1 (en) 2004-03-11 2005-09-22 Genentech, Inc. Process for producing polypeptides
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
BRPI0513639A (pt) 2004-08-06 2008-05-13 Genentech Inc métodos de previsão da sensibilidade, métodos de indução da apoptose e métodos de tratamento de disfunção em mamìferos e de cáncer
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
CN111320384A (zh) * 2019-04-04 2020-06-23 株式会社小原 光学玻璃的制造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
EP0550629A1 (en) 1990-08-17 1993-07-14 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
KR101004174B1 (ko) * 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2256464A1 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
AU733380B2 (en) 1996-10-03 2001-05-10 Regents Of The University Of Michigan, The Nucleotide and protein sequence of mammastatin and methods of use
BR9612752A (pt) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
ES2331900T3 (es) 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
JP2002508962A (ja) * 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
WO2001018055A1 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
AU7053000A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
EP2322165A1 (en) * 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Similar Documents

Publication Publication Date Title
JP2011088897A5 (enExample)
JP2011505522A5 (enExample)
JP2013522425A5 (enExample)
JP2013546230A5 (enExample)
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
JP2014500291A5 (enExample)
JP2014530840A5 (enExample)
JP2013140343A5 (enExample)
MY173847A (en) Disinfectant compositions and uses thereof
JP2011510778A5 (enExample)
JP2012516348A5 (enExample)
WO2015038689A3 (en) Cationic antiseptic compositions
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP2628485A4 (en) New use of chemical ingredients in cynomorium as phytoestrogen
Doi et al. A two-country dynamic model of international trade and endogenous growth: Multiple balanced growth paths and stability
JP2011008097A5 (enExample)
PT2699545T (pt) Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico
PL392957A1 (pl) Preparat zawierający dodatek zoohigieniczny poprawiający warunki zoohigieniczne w pomieszczeniach gospodarskich i zastosowanie preparatu
CL2013001596A1 (es) Proceso de purificacion y estabilizacion de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).
EP2353384A3 (en) Disinfectant formulations that remain liquid at low temperature
JP2014159381A5 (enExample)
Zihan Zaozhuang Textile Industrial Park: Opportunities and Challenges
Smith How the Religious Right Shaped Lesbian and Gay Activism